---
layout: default
title: Alfuzosin Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 22
evidence_level: L5
indication_count: 0
---

# Alfuzosin Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alfuzosin Hydrochloride: Evaluation Pending – No Repurposing Candidates Generated

---

## One-Sentence Summary

Alfuzosin Hydrochloride is a selective alpha-1 adrenergic receptor antagonist, widely recognised for treating lower urinary tract symptoms associated with Benign Prostatic Hyperplasia (BPH).
The TxGNN model **did not generate any repurposing predictions** for this drug in the current evaluation run, most likely because no DrugBank ID was resolved and the mechanism of action data is absent.
This evidence pack is incomplete; critical data gaps prevent a full repurposing assessment, and a **Hold** decision is recommended until the gaps are remediated.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in evidence pack |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A – model returned no candidates |
| South Africa Market Status | Not registered |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN knowledge graph links a drug to disease nodes via its DrugBank ID. For this evaluation run, no DrugBank ID was resolved for Alfuzosin Hydrochloride, and the mechanism of action (MOA) field is unpopulated. Without these anchors, the model cannot traverse the knowledge graph and therefore returns zero repurposing candidates.

Based on established pharmacology, Alfuzosin Hydrochloride is a post-synaptic alpha-1 adrenoceptor antagonist. It selectively relaxes smooth muscle in the prostate, prostate capsule, prostatic urethra, and bladder neck, reducing bladder outlet resistance. This mechanism is well-characterised and is associated with a known DrugBank entry (DB00346 — to be verified and populated). Once the identifier is resolved, TxGNN may identify mechanistically plausible repurposing candidates in conditions involving adrenergic signalling, such as hypertension, Raynaud's phenomenon, or post-traumatic stress disorder — all areas where alpha-1 antagonists have been explored in the literature.

---

## South Africa Market Information

Alfuzosin Hydrochloride currently has **no SAHPRA-registered products** in South Africa. There are no active licences on record in this evidence pack.

> **Note for evaluators:** Alfuzosin extended-release tablets (e.g., Xatral XL 10 mg) are approved in multiple jurisdictions including the EU, US (FDA), and Australia (TGA). A formal SAHPRA registration search is recommended to confirm whether any products hold or previously held South African registration.

---

## Safety Considerations

No SAHPRA-approved Professional Information (PI) data, key warnings, or contraindication records were retrieved in this evaluation run.

> Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

For reference, the following are well-known safety considerations for alpha-1 antagonists of this class that evaluators should verify against the official PI:

- **First-dose hypotension**: Orthostatic hypotension risk, particularly in elderly patients or those on antihypertensives
- **QT prolongation**: Class effect concern at higher exposures; caution with concomitant QT-prolonging agents
- **Intraoperative Floppy Iris Syndrome (IFIS)**: Risk during cataract surgery; ophthalmologist notification required prior to any ocular procedure
- **Hepatic impairment**: Contraindicated in severe hepatic impairment due to altered metabolism

These points are for contextual awareness only and **must not be used in clinical decision-making** until confirmed from the official SAHPRA PI.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model returned no repurposing candidates because the DrugBank ID was not resolved and the MOA data is absent — both blocking inputs for the prediction pipeline. The drug is also currently unregistered with SAHPRA, and all safety data fields are unpopulated. This evidence pack cannot support a repurposing evaluation in its current state.

**To proceed, the following is needed:**

- [ ] **Resolve DrugBank ID**: Confirm and populate the DrugBank identifier for Alfuzosin Hydrochloride (expected: DB00346)
- [ ] **Retrieve MOA data**: Query the DrugBank API using the confirmed ID to populate mechanism of action fields
- [ ] **Retrieve safety data**: Download and parse the SAHPRA-approved PI (or nearest jurisdiction equivalent) to extract key warnings, contraindications, and drug interactions
- [ ] **Re-run TxGNN predictions**: Execute the full prediction pipeline with the resolved DrugBank ID
- [ ] **Confirm SAHPRA registration status**: Conduct a direct search on the SAHPRA online register to verify historical or current product licences
- [ ] **Re-issue evidence pack**: Once data gaps DG001 and DG002 are resolved, regenerate the full evidence pack and re-trigger this report

---

> ⚠️ **YMYL Disclaimer**: This report is generated for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any application. Clinicians should refer to the SAHPRA-approved Professional Information for prescribing guidance.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

